Method and Kit For CCR2 Expression Profiling And Disease Stratification
AssigneesRutgers, The State University of New Jersey, Plumeria Therapeutics, Inc.
InventorsLei Yu, Thomas P. Richardson
Life of this patent
Estimating the term…
Abstract
Methods of treating disease include measuring a CCR2 profile of a patent, selecting a CCR2 antagonist based on the CCR2 profile of the patient, and administering the CCR2 antagonist to the patient. Methods for stratifying one or more patients for pain medication based on a CCR2 profile include measuring a CCR2 profile of one or more patients and partitioning the one or more patients into predetermined groups or subgroups based on the CCR2 profile of the one or more patients. Kits for performing the methods are also described.
Claims22
A method for treating a disease in a patient in need thereof, the method comprising:
- a) measuring a CCR2 profile of the patient, the CCR2 profile comprising a profile of CCR2 isoform A, CCR2 isoform B, or both, each CCR2 isoform comprising one or more respective polymorphisms;
- b) selecting a compound based on the CCR2 profile of the patient, wherein the selected compound is an antagonist or agonist of at least one polymorphism identified from the measured CCR2 profile of the patient;
- c) administering the selected compound to the patient.
2-62. (canceled)
A kit for generating a profile of CCR2A and CCR2B isoform expression levels for a human subject, the kit comprising:
- a) one or more reagents for measuring a CCR2 profile of the patient, the CCR2 profile comprising a profile of CCR2 isoform A, CCR2 isoform B, or both, each CCR2 isoform comprising one or more respective polymorphisms, wherein the one or more reagents comprises a forward primer comprising a sequence selected from SEQ ID NOs:
- 7 through 15 and a reverse primer comprising a sequence selected from SEQ ID NOs:
- 16 through 28.
64-68. (canceled)
A method for generating a profile of CCR2A and CCR2B isoform expression levels for a human subject, the method comprising:
- a) obtaining a sample from the human subject;
- b) extracting RNA from the sample;
- c) performing reverse transcription on the extracted RNA to generate cDNA;
- d) amplifying the cDNA by performing polymerase chain reaction (PCR) by using a forward primer comprising a sequence selected from SEQ ID NOs:
- 7 through 15 and a reverse primer comprising a sequence selected from SEQ ID NOs:
- 16 through 28;
- and
- e) quantifying CCR2A and CCR2B isoform expression levels from the amplified cDNA.
Dependencies are inferred from the claim text.